-          ASC30 oral once-daily tablet demonstrated approximately 2.3- fold  to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison . -          Higher drug exposure and favorable tolerability profile positions ASC30 oral once-daily tablet favorably compared to orforglipron.

CALGARY, Canada (Aug. 27, 2025 ) – TheNewswire - Pambili Natural Resources Corporation ("Pambili" or the "Company") (TSX-V: PNN) is pleased to announce that it has secured C$138,500 as the first tranche (“Tranche”) of the C$1-million non-brokered private placement (the “Offering”), previously announced on June 23, 2025. As announced on July 3, 2025, the Company is subject to a Failure to File Cease Trade Order (“FFCTO”) issued by the Alberta Securities Commission (the “ASC”). Accordingly, the Company has applied to the ASC for a partial revocation of the FFCTO to enable the closing of the Tranche.

Following a careful analysis of the Zacks Transportation Shipping industry, we advise buying stocks like LPG, ASC and ESEA.

ASC, DDS and HCSG made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 21, 2025.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

-  Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor ( GLP-1R ) and GIP receptor ( GIPR ) , resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (DIO) mouse model. -  Combination of a low dose of ASC47 with ASC31 demonstrated statistically significantly greater efficacy than a combination of a low dose of ASC47 with tirzepatide, 44.8% compared to 38.1%, respectively, in the DIO mouse model.

The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in Ardmore Shipping (ASC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

-         The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy.  -          ASC47 low dose in combination with tirzepatide demonstrated statistically significantly greater increase in efficacy than ASC47 low dose in combination with semaglutide, 87% vs 55%, respectively, in the DIO mouse model.

Ardmore Shipping stands out in a volatile sector with disciplined capital allocation, a modern eco-friendly fleet, and a balanced revenue model blending spot and time charters. The company boasts low leverage, strong cash generation, and operational flexibility, supporting resilience even as shipping rates normalize from post-pandemic highs. My DCF analysis suggests Ardmore is undervalued, with a fair value of $15.95 per share—implying nearly 50% upside from current levels.